200 Users Online
Small Interfering RNA Market Segmented By indication such as Cardiovascular diseases, Oncology, Central Nervous system disorders, Respiratory disorders, Genetic disorders, Renal diseases, Others with route of administration such as Intravenous, Oral, Intraperitoneal, Others
Over-expressed disease-causing gene is controlled and degraded using small interfering RNA which is one of the genetic medicine. Small interfering RNA is used for pathway identification and analysis such as cytokinesis, cell defence mechanism and insulin signalling. This also contributes to target validation for numerous disorders like cancer, AIDS, hepatitis, cardiovascular diseases and others.
Artificial small interfering RNA induced in body destroys the target mRNA and regulates protein synthesis. Small interfering RNA are target specific will less side effects owing significant market growth during the forecast period. According to the American Heart Association (AHA), approximately 86.2 million people suffer from one of the kinds of cardiovascular diseases in the U.S.
Covid-19 has led to a shift in focus of leading biopharmaceuticals towards developing coronavirus cure. Delay in manufacturing and supply chain activities due to lockdown across several countries impact small interfering RNA market growth.
There has been a delay of clinical research activities in small interfering RNA market due to the shift of focus on finding coronavirus cure among leading biopharmaceuticals. On the other hand, there has been a significant reduction in diagnosis and treatment adoption rate owing to decreased patient visits to healthcare facilities.
Approval and commercialization of new therapeutics are expected to propel the growth of small interfering RNA market. For instance, in 2018, the U. S. Food and Drug Administration approved first small interfering RNA drug known as Onpattro by Alnylam Pharmaceuticals, used for the treatment of rare and genetic diseases.
The rise in prevalence of chronic disorders globally boosts small interfering RNA market growth. Increasing collaborative research and development activities among leading biopharmaceutical innovative players fuel small interfering RNA market growth.
In March 2020, Silence Therapeutics AG and AstraZeneca PLC announced a collaboration to develop small interfering RNA therapies for cardiovascular, renal, metabolic and respiratory diseases treatment. Toxic effects caused by the use of small interfering RNA therapy challenges the growth of small interfering RNA market.
|Based on indication||
|Based on the route of administration||
|Based on the distribution channel||
Based on application, the small interfering RNA market is dominated by oncology with the increasing prevalence of cancer cases across the globe. Cardiovascular diseases segment is expected to have a significant growth rate in small interfering RNA market during the forecast period. The intravenous route of administration is most common in small interfering RNA market.
Whereas, with the increase of research and development activities oral drugs are expected to increase demand in small interfering RNA market during the forecast period. Hospital pharmacies is the leading distribution channel followed by retail pharmacies in the small interfering RNA market. Globally, online pharmacies will have significant growth rate with increased adoption of e-commerce activities in small interfering RNA market.
North America will continue to dominate small interfering RNA market with a high rate of approvals and commercialization in the region. Increase in expenditure towards research and development activities in North America propels the demand for small interfering RNA market. Europe holds the second position with the availability of advanced technology and developed healthcare infrastructure in small interfering RNA market.
Asia-Pacific region is expected to observe exponential growth during the forecast period due to the rise in healthcare expenditure by the government for improving healthcare infrastructure contributing towards small interfering RNA market. The Middle East and Africa are untapped regions with the least growth rate due to limited healthcare investments in small interfering RNA market.
Major players in small interfering RNA market include AstraZeneca PLC, Alnylam Pharmaceuticals, Sanofi-Genzyme, GSK, GE Dharmacon, Silent Therapeutics AG, Arbutus Biopharma Corp., Marina Biosciences, Bneitech Biopharma, Arrowhead Research Corp., Sylentis S.A., Genecon Biotechnologies, Ionis Pharmaceuticals, Quark Pharmaceuticals and others.
The research report on small interfering RNA market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.
It also contains projections using a suitable set of assumptions and methodologies. The research report on small interfering RNA market provides analysis and information according to market segments such as drug class, route of administration, application, and region.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.